Atenolol in hypertension: Is it a wise choice?

Lancet

Volumn 364, Issue 9446, 2004, Pages 1684-1689

  Carlberg, Bo ^a   Samuelsson, Ola ^b   Lindholm, Prof Lars Hjalmar ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE;

EID: 7644236592     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17355-8     Document Type: Article

References (38)

1. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 21:2003;1011-1053
2. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 304:1992;405-412
3. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 317:1998;713-720
4. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;995-1003
5. Sever P, Dahlöf P, Poulter NR, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rational, and outline protocol. J Human Hypertens. 15:(suppl 1):2001;S11-S12
6. Messerli FH, Beevers DG, Franklin SS, Pickering TG. Beta-blockers in hypertension: the emperor has no clothes - an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens. 16:2003;870-873
7. Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet. 362:2003;591-592
8. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 318:1999;1730-1737
9. Dahlöf B, Lindholm LH, Hanson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285
10. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 354:1999;1751-1756
11. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet. 353:1999;611-616
12. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 356:2000;359-365
13. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA. 289:2003;2073-2082
14. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 290:2003;2805-2816
15. SHEP Cooperative Research Group: prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
16. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal In Hypertension Treatment (INSIGHT). Lancet. 356:2000;366-372
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcome in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 288:2002;2981-2997
18. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke. 24:1993;543-548
19. Eriksson S, Olofsson BO, Wester PO. Atenolol in the secondary prevention after stroke. Cerebrovasc Dis. 5:1995;21-25
20. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 293:1986;1145-1151
21. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 5:1987;561-572
22. Zanchetti A, Bond MG, Henning M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 106:2002;2422-2427
23. The Steering Committee of the HAPPHY Trial. MAPHY and the two arms of HAPPHY. JAMA. 262:1989;3273-3274
24. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA. 283:2000;1967-1975
25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus α-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 42:2003;239-246
26. Law MR, Wald NJ, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 326:2003;1427-1434
27. Law MR, Wald NJ, Morris J. Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy. Health Technol Assess. 7:2003;no 31
28. Parker GW, Michael LH, Hartley CJ, Skinner JE, Entman ML. Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res. 66:1990;259-270
29. Åblad B, Bjurö T, Björkman JA, Edström T, Olsson G. Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone. J Am Coll Cardiol 1991; 17 (suppl): 165.
30. Wikstrand J, Warnhold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension: mortality results from the MAPHY study. JAMA. 259:1988;1976-1982
31. Wikstrand J, Berglund G, Tuomilehto J. Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients: review of present evidence. Circulation. 84:(suppl 6):1991;I93-100
32. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmeider RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 115:2003;41-46
33. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens. 8:1995;229-236
34. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 101:2000;1653-1659
35. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep. 2:2000;64-70
36. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 20:2002;71-78
37. CIBIS-II Investigators and Committees. The Cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13
38. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 353:1999;2001-2007